Laili Nurzaidah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laili Nurzaidah has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Indra Mahendra
Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia
1 shared publication - Agustina Tri Endharti
Department of Parasitology Faculty of Medicine Universitas Brawijaya Malang Indonesia ub.ac.id
1 shared publication - Andi Permana
Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia
1 shared publication Andy Pranata Kusuma
Faculty of Medicine, Universitas Airlangga, Surabaya, 60286, Indonesia
1 shared publicationAnggara Dwi Samudra
Department of Sport Health Science, Faculty of Medicine, Universitas Airlangga, Surabaya, 60286, Indonesia
1 shared publication- Anisa Asmiragani
Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia
1 shared publication
Latest Publications
- Open Access
- 1 March 2024
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 12 (2) , 303-322
Anticancer activity of Hedyotis corymbosa nanoliposomes targeting estrogen receptor-alpha in breast cancer cells: In silico and in vitro studies
Context: Breast cancer expresses high levels of the estrogen receptor alpha (ER-α). Aims: To investigate the potential anticancer activity of nanoliposome Hedyotis corymbosa in breast cancer cells by specifically targeting the ER-α through a combination of in silico and in vitro studies. Methods: This study used molecular docking to analyze the interaction between ER-α and active compounds from H. corymbosa. In vitro studies, the H. corymbosa extract was converted into nanoliposomes. The nanoliposomes' characteristics were examined, combined with tamoxifen, and applied to breast cancer cell cultures. Viability, proliferation, and ER-α expression were assessed, and statistical analysis was performed (p<0.05). Results: The findings show that H. corymbosa compounds, especially rutin, inhibit ER-α binding and act as a substrate for P-glycoprotein. Extract H. corymbosa selectively decreases viability in breast cancer cells (T47D) compared to non-cancerous cells (NIH3T3). Combining extracts with tamoxifen at 10 mg/mL enhances treatment efficacy. The combined treatment is effective for up to 72 h, reducing T47D breast cancer cell proliferation. Nanoliposomes derived from extract exhibit favorable characteristics, including a spherical shape, uniform size distribution, and stability. Using these nanoliposomes at 100 μg/mL with tamoxifen significantly reduces ER-α expression (p<0.05) without affecting cell viability. Conclusions: Compounds from H. corymbosa, especially rutin, inhibit ER-α binding. H. corymbosa nanoliposomes are stable for drug delivery. Combining tamoxifen with nanoliposomes at 100 μg/mL reduces ER-alpha expression. This shows potential for breast cancer treatment, but validation through further research and clinical trials is necessary.
- 1 March 2024
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 12 (2) , 303-322
Open AccessAnticancer activity of Hedyotis corymbosa nanoliposomes targeting estrogen receptor-alpha in breast cancer cells: In silico and in vitro studies
Context: Breast cancer expresses high levels of the estrogen receptor alpha (ER-α). Aims: To investigate the potential anticancer activity of nanoliposome Hedyotis corymbosa in breast cancer cells by specifically targeting the ER-α through a combination of in silico and in vitro studies. Methods: This study used molecular docking to analyze the interaction between ER-α and active compounds from H. corymbosa. In vitro studies, the H. corymbosa extract was converted into nanoliposomes. The nanoliposomes' characteristics were examined, combined with tamoxifen, and applied to breast cancer cell cultures. Viability, proliferation, and ER-α expression were assessed, and statistical analysis was performed (p<0.05). Results: The findings show that H. corymbosa compounds, especially rutin, inhibit ER-α binding and act as a substrate for P-glycoprotein. Extract H. corymbosa selectively decreases viability in breast cancer cells (T47D) compared to non-cancerous cells (NIH3T3). Combining extracts with tamoxifen at 10 mg/mL enhances treatment efficacy. The combined treatment is effective for up to 72 h, reducing T47D breast cancer cell proliferation. Nanoliposomes derived from extract exhibit favorable characteristics, including a spherical shape, uniform size distribution, and stability. Using these nanoliposomes at 100 μg/mL with tamoxifen significantly reduces ER-α expression (p<0.05) without affecting cell viability. Conclusions: Compounds from H. corymbosa, especially rutin, inhibit ER-α binding. H. corymbosa nanoliposomes are stable for drug delivery. Combining tamoxifen with nanoliposomes at 100 μg/mL reduces ER-alpha expression. This shows potential for breast cancer treatment, but validation through further research and clinical trials is necessary.
- Open Access
- 29 July 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 862
The global prevalence and association between the risk of myocarditis and mRNA-based COVID-19 vaccination: A network meta-analysis
Background: Cases of myocarditis development have been reported after administration of messenger ribonucleic acid (mRNA)-based coronavirus disease (COVID-19) vaccines. However, the reports vary among the studies, and the types of mRNA vaccines with potential to cause myocarditis remain unidentified. The objective was to assess the cumulative prevalence of myocarditis and determine the association between myocarditis and mRNA-based COVID-19 vaccination. Methods: We performed a network meta-analysis by searching articles in PubMed, Scopus, and Web of Science. Information on the prevalence of myocarditis after the mRNA-based COVID-19 vaccination was collected from each study. Analysis was performed by calculating the pooled prevalence rate, and the association was determined using the Z-test. Data networking was performed using the Bayesian method. Results: A total of 18 papers was included in our analysis. We found that the cumulative prevalence of myocarditis was 1.7, 1.9, 1.2, and 1.1 per 100,000 population after vaccination with different types of mRNA-based COVID-19 vaccines, namely all mRNA COVID-19 vaccines, BNT162b1, mRNA-1273, and the combination of BNT162b1 and mRNA-1273, respectively. Moreover, the results revealed that BNT162b1 vaccination increased the risk of myocarditis by 1.64- and 1.71-folds compared to mRNA-1273 and the combination of BNT162b2 and mRNA-1273, respectively. Similar risks of developing myocarditis were observed after mRNA-1273 and the combination of BNT162b1 and mRNA-1273 vaccination. Conclusions: Our findings suggest the cumulative prevalence of myocarditis after mRNA-based COVID-19 vaccination with maximum prevalence was observed after BNT162b2 administration. BNT162b2 was associated with a higher risk of developing myocarditis than the other mRNA-based COVID-19 vaccines.
- 29 July 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 862
Open AccessThe global prevalence and association between the risk of myocarditis and mRNA-based COVID-19 vaccination: A network meta-analysis
Background: Cases of myocarditis development have been reported after administration of messenger ribonucleic acid (mRNA)-based coronavirus disease (COVID-19) vaccines. However, the reports vary among the studies, and the types of mRNA vaccines with potential to cause myocarditis remain unidentified. The objective was to assess the cumulative prevalence of myocarditis and determine the association between myocarditis and mRNA-based COVID-19 vaccination. Methods: We performed a network meta-analysis by searching articles in PubMed, Scopus, and Web of Science. Information on the prevalence of myocarditis after the mRNA-based COVID-19 vaccination was collected from each study. Analysis was performed by calculating the pooled prevalence rate, and the association was determined using the Z-test. Data networking was performed using the Bayesian method. Results: A total of 18 papers was included in our analysis. We found that the cumulative prevalence of myocarditis was 1.7, 1.9, 1.2, and 1.1 per 100,000 population after vaccination with different types of mRNA-based COVID-19 vaccines, namely all mRNA COVID-19 vaccines, BNT162b1, mRNA-1273, and the combination of BNT162b1 and mRNA-1273, respectively. Moreover, the results revealed that BNT162b1 vaccination increased the risk of myocarditis by 1.64- and 1.71-folds compared to mRNA-1273 and the combination of BNT162b2 and mRNA-1273, respectively. Similar risks of developing myocarditis were observed after mRNA-1273 and the combination of BNT162b1 and mRNA-1273 vaccination. Conclusions: Our findings suggest the cumulative prevalence of myocarditis after mRNA-based COVID-19 vaccination with maximum prevalence was observed after BNT162b2 administration. BNT162b2 was associated with a higher risk of developing myocarditis than the other mRNA-based COVID-19 vaccines.
- Open Access
- 26 October 2019
- Published by Brawijaya University in JSMARTech
- Vol. 1 (1) , 1-5
Virtual Prediction of Thymoquinone and β-Glucan Interaction as Estrogen Receptor-Alpha (ER-α receptor) May Reducing on The Breast Cancer Signaling Pathway
Virtual Prediction of Thymoquinone and β-Glucan Interaction as Estrogen Receptor-Alpha (ER-α receptor) May Reducing on The Breast Cancer Signaling Pathway
- 26 October 2019
- Published by Brawijaya University in JSMARTech
- Vol. 1 (1) , 1-5
Open AccessVirtual Prediction of Thymoquinone and β-Glucan Interaction as Estrogen Receptor-Alpha (ER-α receptor) May Reducing on The Breast Cancer Signaling Pathway
Virtual Prediction of Thymoquinone and β-Glucan Interaction as Estrogen Receptor-Alpha (ER-α receptor) May Reducing on The Breast Cancer Signaling Pathway